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Abstract
Objective Whether alcohol consumption inﬂuences
ovarian cancer risk is unclear. Therefore, we investi-
gated the association between alcohol intake at various
ages and risk of ovarian cancer.
Methods Among 90,371 eligible members of the
California Teachers Study cohort who completed a
baseline alcohol assessment in 1995–1996, 253 women
were diagnosed with epithelial ovarian cancer by the
end of 2003. Multivariate Cox proportional hazards
regression analysis was performed to estimate relative
risks (RRs) and 95% conﬁdence intervals (CIs).
Results Consumption of total alcohol, beer, or liquor
in the year prior to baseline, at ages 30–35 years, or at
ages 18–22 years was not associated with risk of ovar-
ian cancer. Consumption of at least one glass per day
of wine, compared to no wine, in the year before
baseline was associated with increased risk of devel-
oping ovarian cancer: RR = 1.57 (95% CI 1.11–2.22),
Ptrend = 0.01. The association with wine intake at
baseline was particularly strong among peri-/post-
menopausal women who used estrogen-only hormone
therapy and women of high socioeconomic status.
Conclusions Alcohol intake does not appear to affect
ovarian cancer risk. Constituents of wine other than
alcohol or, more likely, unmeasured determinants of
wine drinking were associated with increased risk of
ovarian cancer.
Keywords Ovarian cancer  Alcoholic beverages 
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Introduction
Consistent evidence that moderate alcohol consump-
tion increases the risk of breast cancer, presumably by
elevating estrogen and androgen levels [1], suggests
that alcohol intake might also inﬂuence the develop-
ment of other hormone-related malignancies, such as
ovarian cancer. From a public health standpoint, this
hypothesis is attractive since alcohol consumption
could represent a readily modiﬁable ovarian cancer
risk factor, whereas other risk factors, particularly
reproductive characteristics [2, 3], are generally less
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examining the association between alcohol and ovarian
cancer risk have been discrepant, with published re-
ports of mostly null [3–19], some positive [15, 16, 20,
21], and some inverse associations [14, 17, 22–25],
including occasional variation in associations by type of
alcohol and/or subgroup of ovarian cancer cases. No
systematic differences in ﬁndings are apparent between
case–control and cohort studies.
Although ethanol itself is not a direct ovarian car-
cinogen, it could inﬂuence ovarian cancer risk through
effects on steroid hormones, especially estrogens,
which are believed to play a primary role in ovarian
carcinogenesis [26]. In pre-menopausal women, mod-
erate to high alcohol consumption is associated with
elevated levels of total and bioavailable estrogens and
androgens [27–29], reduced fertility [30, 31], and de-
creased menstrual cycle variability and length, result-
ing in increased cumulative estrogen exposure [32]. In
post-menopausal women, moderate alcohol intake
markedly increases circulating estrogen levels in hor-
mone therapy (HT) users [33, 34], and it may elevate
estrogen and androgen levels in women not using HT
[35]. Other mechanisms for alcohol-related carcino-
genesis include alteration of gonadotropin levels, pro-
motion of DNA damage, impaired folate metabolism
and DNA hypomethylation, inhibition of carcinogen
detoxiﬁcation or clearance, and increased metastatic
potential of tumor cells [1].
Given the biologic plausibility of a role of alcohol
intake in ovarian cancer etiology, we examined the
association between alcohol consumption and risk of
ovarian cancer in a prospective cohort in which base-
line alcohol consumption was associated with increased
breast cancer risk [36, 37]. With data on past and
baseline intake of speciﬁc alcoholic beverages, as well
as information on a variety of demographic and
behavioral factors, we were also able to explore the
importance of drinking patterns and potential effect
modiﬁers of any association.
Methods
Study population
The California Teachers Study (CTS) cohort includes
133,479 active and retired female public school teach-
ers and administrators who were members of the Cal-
ifornia State Teachers Retirement System and
returned a mailed questionnaire in 1995–1996 [38]. The
questionnaire assessed a range of potential cancer risk
factors including menstrual and reproductive history,
personal and family medical history, physical activity,
dietary intake during the previous year (using a food-
frequency questionnaire and portion-size assessment
[39–42]), alcohol and tobacco use, and other factors.
All women provided written informed consent to par-
ticipate in the study, and the study protocol was ap-
proved by the institutional review boards of all
participating institutions.
For this analysis, we excluded women (in a hierar-
chical manner) as follows: those who 1.) lived outside
of California at baseline (n = 8,867); 2.) did not pro-
vide adequate information on personal history of
cancer (n = 662); 3.) consented to participate only in
analyses of breast cancer (n = 18); 4.) reported having
had ovarian cancer before baseline or were identiﬁed
by the California Cancer Registry as having been
previously diagnosed with ovarian cancer (n = 640);
5.) reported having had a bilateral oophorectomy be-
fore baseline (n = 14,422); 6.) were aged 85 years or
older at baseline (n = 1,874); 7.) reported never hav-
ing had a ﬁrst menstrual period (n = 51); 8.) provided
multiple invalid, inconsistent, or blank responses to
the dietary questionnaire (n = 2,942); 9.) reported
food consumption that was judged to be implausibly
low (i.e., < 600 calories/day) or high (i.e., > 5,000 cal-
ories/day) (n = 1,565 and 69, respectively); or 10.)
provided invalid, missing, or inconsistent data with
respect to alcohol intake during the previous year
(n = 5,094) or the earlier two periods evaluated
(n = 6,904). Of the 90,371 remaining women included
in this analysis, 227 were diagnosed with invasive
epithelial ovarian cancer and 26 were diagnosed with
borderline epithelial ovarian cancer (ICD-O-3 site
C569, excluding non-epithelial ovarian cancer cases
[morphology codes 8240–8245, 8590–8671, and 9060–
9989] [43]) after joining the cohort and on or before 31
December 2003.
Alcohol assessment
Participants reported average weekly consumption of
beer, wine/champagne, and cocktails/liquor at ages 18–
22 years, at ages 30–35 years, and in the year prior to
baseline. Available response categories for average
number of drinks per week were none, £ 3, 4–10,
11–17, 18–24, and ‡ 25. A typical drink was deﬁned as
one bottle, can, or glass of beer; one glass of wine,
champagne, or wine cooler; or one cocktail, shot, or
mixed drink of liquor. A single drink of beer, wine, or
liquor was assumed to contain 13.2, 11.1, or 15.0 grams
of alcohol, respectively. Based on these standards,
daily intake of grams of alcohol from each type of
drink was calculated for each woman during each time
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123period. Alcohol intake in the cohort was reproducible
(r = 0.87) and valid compared to multiple 24–hour re-
calls (r = 0.74) (Pamela Horn-Ross, unpublished data).
Daily consumption of alcohol from beer was cate-
gorized as 0, < 13.2, or ‡ 13.2 grams/day; alcohol from
wine was categorized as 0, < 11.1, or ‡ 11.1 grams/day;
alcohol from liquor was categorized as 0, < 15.0,
or ‡ 15.0 grams/day; and total alcohol was categorized
as 0, < 10.0, 10.0 to < 20.0, or ‡ 20.0 grams/day. These
categories were deﬁned based on the grams of alcohol
per standard drink, and on ﬁndings from previous
analyses of alcohol intake and breast cancer risk in the
CTS [36, 37].
Based on their drinking patterns in any two time
periods (ages 18–22 years and baseline, ages
30–35 years and baseline, or ages 18–22 years and
30–35 years), women were categorized as having been
non-drinkers, moderate drinkers (in the middle cate-
gory or categories of intake), or heavy drinkers (in the
highest category of intake) in both time periods; or
decreasing or increasing drinkers if their intake
changed between the earlier and the later time period.
For each type of alcoholic drink and each time period,
women also reported how many days per week they
usually had at least one drink. Women were catego-
rized as non-drinkers, as drinking alcohol on 1–4 days/
week, or as drinking alcohol on ‡ 5 days/week [37].
Residence-based measures
Based on residential address at entry, women were
geocodedtocensusblockgroups.Toobtainameasureof
each cohort member’s relative socioeconomic status
(SES), all 1990 census block groups in the state of Cali-
fornia were ranked by three measures, according to de-
ciles based on the statewide adult population:
percentage of adults over age 25 years who had com-
pletedacollegedegreeorhigher;medianfamilyincome;
and percentage of adults employed in managerial/pro-
fessional occupations [44]. A summary SES metric was
created by adding the scores (1 through 10) across these
attributes; participants were then categorized into de-
ciles or quartiles of the total score. Women were also
categorized by median family income in their census
block group, based on deciles in the cohort.
Residential census block groups were categorized as
rural, town, small city, metropolitan suburban, or
metropolitan urban based on population size and
density [44]. Women were also classiﬁed as residents of
the Greater San Francisco Bay Area (Alameda, Contra
Costa, Marin, Monterey, San Benito, San Francisco,
San Mateo, Santa Clara, and Santa Cruz Counties); the
Southern Coastal area (Orange, Los Angeles, and San
Diego Counties); or the rest of California [45].
Follow-up
Person-time was accrued from the date of completion
of the baseline questionnaire until the date of ﬁrst
diagnosis with borderline or invasive ovarian cancer,
relocation out of California, death, or 31 December
2003, whichever occurred earliest. Information on
incident ovarian cancer and tumor characteristics was
obtained through annual linkage of cohort members to
the California Cancer Registry (CCR) based on full
name, date of birth, address, and social security
number, including manual review of possible matches.
The CCR is the population-based cancer registry that
covers the entire state of California, has agreements
with 13 other states for case-sharing purposes, and
maintains high-quality data standards as part of the
National Cancer Institute’s Surveillance, Epidemiol-
ogy, and End Results program. Reporting of new
cancer diagnoses to the CCR has been mandated by
California state law since 1985, and coverage is esti-
mated to be 99% complete [46], such that all members
of the CTS cohort are effectively in active follow-up for
cancer outcomes as long as they reside in California.
Date and cause of death are ascertained through
linkages with the California state mortality ﬁle and the
national Social Security Administration death master
ﬁle, as well as reports from relatives. Address changes
are obtained through annual mailed newsletters, noti-
ﬁcations by participants, and record linkages with the
California Department of Motor Vehicles, the US
Postal Service National Change of Address database,
and other sources.
Statistical analysis
Multivariable Cox proportional hazards regression
analysis was performed to evaluate the association be-
tween alcohol consumption and risk of ovarian cancer,
using ages at the start and end of follow-up (in days) to
deﬁne the time scale. Models were adjusted for race
(White or non-White), total daily caloric intake (con-
tinuous), parity (0, 1–2, or ‡ 3 full-term pregnancies),
use of oral contraceptives (never, < 5 years, or ‡ 5
years), average strenuous physical exercise ( < 0.5, 0.5–
3.99, or ‡ 4 hours/week during lifetime up to age
54 years), menopausal status/use of HT (pre-meno-
pausal, unknown menopausal status, or peri-/post-
menopausal and: never used HT, used combination
estrogen-progestin HT, used a mixture of combination
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123and estrogen-only (‘‘mixed’’) HT, used estrogen-only
HT for £ 5 years, used estrogen-only HT for > 5 years,
used estrogen-only HT for an unknown duration, or
unknown HT use), and an interaction between
menopausal status/HT use and the time scale (because
menopausal status/HT use violated the proportionality
assumption), and were stratiﬁed by age at baseline (in
years). These potential confounders were chosen based
on statistically signiﬁcant (p-value £ 0.05) associations
with risk of ovarian cancer, and on prior knowledge of
ovarian cancer risk factors. Missing values were coded
as dummy variables, none of which were found to be
associated with ovarian cancer risk. We tested the
assumption of proportional hazards for each alcohol
variable using signiﬁcance tests of interactions with the
time scale and visual examination of scaled Schoenfeld
residual plots [47], and found no violations of the pro-
portionality assumption.
Hazard rate ratios, presented as relative risks (RR),
and corresponding 95% conﬁdence intervals (CI) were
estimated for each type of alcoholic beverage, com-
paring categories of consumption to non-drinkers of
that alcohol type as the reference group. Tests for
linear trend across exposure categories were conducted
using the median of each category coded as an ordinal
variable. The median of the highest category of beer,
wine, or liquor intake was equal to the lower boundary
because most women in those categories reported
consuming one drink per day.
Analyses were ﬁrst performed for all eligible women,
and then repeated with restriction to women who were
peri- or post-menopausal at baseline. In addition, anal-
yseswereperformed with restrictionto cases of invasive
ovarian cancer (excluding borderline cases) or serous
ovarian cancer (ICD-O-3 morphology codes 8441–8462
and 9014 [43]; n = 114). Likelihood ratio tests were
used to evaluate homogeneity of the estimated RR be-
tween strata of women, as well as signiﬁcant differences
in ﬁt between models with and without additional co-
variates.Testsfornon-linearityoftrendwerebasedona
likelihood ratio test comparing models with the expo-
sure coded as an ordinal or a categorical variable [48].
Associations with wine drinking were evaluated using
multivariate logistic regression, using covariates as de-
ﬁned above. All analyses were performed using SAS
Version 9.1 (SAS Institute, Cary, NC).
Results
Distributions of demographic characteristics and
ovarian cancer risk factors in the eligible study cohort
are shown in Table 1. The median length of follow-up
was 2,959 days (8.1 years) and the median age of par-
ticipants at baseline was 50 years. As shown in Table 2,
there was no overall difference in risk of ovarian can-
cer by total alcohol consumption in the year before
baseline, at ages 30–35 years, or at ages 18–22 years.
Similarly, consumption of alcohol from beer or liquor
during any of the three time periods was not signiﬁ-
cantly associated with risk of ovarian cancer. In con-
trast, intake of alcohol from wine during the year
before baseline was associated with statistically signif-
icantly elevated risk of ovarian cancer. After adjusting
for alcohol intake from beer and liquor, as well as
ovarian cancer risk factors, women who drank at least
11.1 grams per day of alcohol from wine—the equiva-
lent of one glass per day—at baseline were at 57%
higher risk of ovarian cancer, compared to women who
did not drink wine (Ptrend = 0.01). Intake of alcohol
from wine at ages 30–35 years or ages 18–22 years was
not signiﬁcantly associated with ovarian cancer risk,
although the estimated RRs were consistent with those
for baseline wine intake.
Intake of speciﬁc alcohol types, beyond total alco-
hol, was associated with ovarian cancer risk, as as-
sessed by comparing a multivariate model with beer,
wine, and alcohol consumption in the year before
baseline to a model with alcohol consumption alone
(p = 0.05, 2 d.f.). Furthermore, the association of wine
consumption with ovarian cancer risk differed from
that of beer or liquor consumption, as assessed by
comparing a multivariate model with beer/liquor and
wine consumption to a model with alcohol consump-
tion (p = 0.02, 1 d.f.). Controlling for total alcohol in-
take did not attenuate the positive association between
wine intake at any time period and risk of ovarian
cancer (data not shown). Women who drank wine only
in the year before baseline (median daily alcohol in-
take = 11.1 grams), relative to non-drinkers, had an
ovarian cancer RR of 1.40 (95% CI 1.01–1.93). In
contrast, risk did not vary between non-drinkers and
women who drank beer or liquor only (median daily
intake of alcohol = 4.5 grams; RR = 1.03 [95% CI
0.58–1.83]) or beer/liquor and wine (median daily
alcohol intake = 11.8 grams; RR = 1.08 [95% CI 0.79–
1.48]). The multivariate RR among women who
exclusively drank at least one glass of wine per day,
compared to non-drinkers, was 1.70 (95% CI 1.10–
2.62). After simultaneously adjusting for wine drinking
during the year before baseline and at ages 18–22 years
and 30–35 years, the RR associated with drinking at
least one daily glass of wine at baseline was 1.33 (95%
CI 0.91–1.96); at ages 30–35 years, RR = 1.01 (95% CI
0.61–1.68); and at ages 18–22 years, RR = 1.28 (95%
CI 0.58–2.87).
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123Table 1 Selected baseline characteristics of the California Teachers Study (CTS) cohort included in the present analysis (n= 90,371)
Characteristic n (%)
Age at baseline (years)
<35 10,456 (11.6%)
35–44 18,546 (20.5%)
45–54 28,275 (31.3%)
55–64 16,229 (18.0%)
65–74 11,496 (12.7%)
75–84 5,369 (5.9%)
Race/ethnicity
White 78,468 (86.8%)
Non-white 11,266 (12.5%)
Unknown 637 (0.7%)
Parity (full-term pregnancies)
None 23,810 (26.3%)
1–2 43,674 (48.3%)
‡3 21,412 (23.7%)
Unknown 1,475 (1.6%)
Oral contraceptive use (years)
None 26,643 (29.5%)
<5 27,608 (30.5%)
‡5 32,463 (35.9%)
Unknown 3,657 (4.0%)
Lifetime strenuous physical activity (average hours/week)
<0.5 25,254 (27.9%)
0.5–3.9 49,467 (54.7%)
‡4.0 15,293 (16.9%)
Unknown 357 (0.4%)
Menopausal status
Pre-menopausal 42,204 (46.7%)
Peri-menopausal 2,202 (2.4%)
Post-menopausal 39,744 (44.0%)
Unknown 6,221 (6.9%)
Hormone therapy (HT) use (peri-/post-menopausal women only)
None 12,968 (30.9%)
Combination estrogen + progestin HT 14,235 (33.9%)
Estrogen-only HT, £5 years 4,342 (10.4%)
Estrogen-only HT, >5 years 4,899 (11.7%)
Estrogen-only HT, unknown duration 332 (0.8%)
Mixed combination and estrogen-only HT 4,776 (11.4%)
Unknown 394 (0.9%)
Region of residence within California
a
Greater San Francisco Bay Area 18,444 (20.4%)
Southern Coastal/Los Angeles Area 35,388 (39.2%)
Other areas 36,483 (40.4%)
Unknown 56 (0.1%)
Type of residence
Rural 12,677 (14.0%)
Town 3,136 (3.5%)
Small city 16,135 (17.9%)
Metropolitan suburban 48,278 (53.4%)
Metropolitan urban 9,038 (10.0%)
Unknown 1,107 (1.2%)
Statewide percentile of socioeconomic status in census block group
a
£49th 18,962 (21.0%)
50–59th 10,199 (11.3%)
60–69th 12,620 (14.0%)
70–79th 14,508 (16.1%)
80–89th 16,864 (18.7%)
90–99th 16,076 (17.8%)
Unknown 1,142 (1.3%)
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Characteristic n (%)
Smoking history
Never 60,868 (67.4%)
Former 24,989 (27.7%)
Current 4,428 (4.9%)
Unknown 86 (0.1%)
Alcohol drinking in the year prior to baseline
None 31,024 (34.3%)
Beer only 2,222 (2.5%)
Wine only 19,365 (21.4%)
Liquor only 2,868 (3.2%)
Beer and liquor only 1,005 (1.1%)
Wine and beer/liquor 33,887 (37.5%)
a See Methods for deﬁnition
Table 2 Relative risks (RRs) and 95% conﬁdence intervals (CIs) for associations between intake of speciﬁc types of alcohol at various
ages and risk of ovarian cancer
Alcohol
type
Time
period
Daily intake
(g/day)
Median
(g/day)
Cases (n)R R
a 95% CI
a RR
b 95% CI
b
Total alcohol
Year before baseline
None 0.0 77 1.00 (reference) —
<10.0 4.5 81 1.04 (0.76, 1.42) —
10.0– < 20.0 11.8 72 1.47 (1.06, 2.03) —
‡20.0 28.2 23 1.15 (0.71, 1.84) —
Ptrend = 0.19
Ages 30–35 years
c
None 0.0 67 1.00 (reference) —
<10.0 7.3 101 1.14 (0.83, 1.56) —
10.0– < 20.0 11.8 47 1.08 (0.74, 1.59) —
‡20.0 29.7 16 0.99 (0.56, 1.71) —
Ptrend = 0.99
Ages 18–22 years
d
None 0.0 131 1.00 (reference) —
<10.0 4.5 62 0.76 (0.55, 1.03) —
10.0– < 20.0 11.8 36 1.26 (0.86, 1.84) —
‡20.0 28.8 9 1.00 (0.50, 1.99) —
Ptrend = 0.63
Beer
Year before baseline
None 0.0 199 1.00 (reference) 1.00 (reference)
<13.2 4.0 51 0.96 (0.70, 1.31) 0.89 (0.64, 1.24)
‡13.2 13.2 3 0.58 (0.19, 1.84) 0.54 (0.17, 1.70)
Ptrend = 0.40 Ptrend = 0.22
Ages 30–35 years
c
None 0.0 180 1.00 (reference) 1.00 (reference)
<13.2 4.0 45 0.81 (0.58, 1.13) 0.75 (0.53, 1.06)
‡13.2 13.2 6 0.72 (0.32, 1.64) 0.73 (0.32, 1.69)
Ptrend = 0.20 Ptrend = 0.16
Ages 18–22 years
d
None 0.0 179 1.00 (reference) 1.00 (reference)
<13.2 4.0 46 0.95 (0.68, 1.32) 0.93 (0.65, 1.33)
‡13.2 13.2 13 1.21 (0.68, 2.16) 1.30 (0.70, 2.39)
Ptrend = 0.67 Ptrend = 0.57
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123Women who drank at least one glass per day of wine
both in an earlier time period (18–22 years or 30–
35 years)andatbaselinewereatsigniﬁcantlyhigherrisk
of ovarian cancer, compared to wine non-drinkers
(Table 3). Results were similar when based on intake at
ages 18–22 years and 30–35 years (data not shown).
Women who were heavy wine drinkers in all three time
periods (n = 5 cases) had over four times the risk of
ovariancancer relativeto women who never drank wine
in any time period (RR = 4.60 [95% CI = 1.76–12.01]),
adjusting for beer and liquor drinking patterns. Mar-
ginallyelevatedriskofovariancancerwasalsoobserved
among women who increased or decreased their wine
intake between ages 18–22 years and either baseline or
ages 30–35 years (latter data not shown). No patterns of
total alcohol, beer, or liquor intake were signiﬁcantly
associated with ovarian cancer risk. Furthermore,
ovarian cancer risk did not vary according to number of
drinking days per week at baseline, whether for total
alcohol, beer, wine, or liquor, although the risk of
ovariancancerroseslightlywithincreasingfrequencyof
wine consumption at baseline (Ptrend = 0.11).
The lack of an association with total alcohol, beer,
or liquor intake, as well as the persistence of the
association between wine intake and risk of ovarian
cancer after adjustment for alcohol consumption, sug-
gested that determinants of wine drinking, or ingredi-
ents of wine other than alcohol, were responsible for
the observed positive association. After mutual
adjustment, older age (up to ages 65–69 years), White
Table 2 continued
Alcohol
type
Time
period
Daily intake
(g/day)
Median
(g/day)
Cases (n)R R
a 95% CI
a RR
b 95% CI
b
Wine
Year before baseline
None 0.0 91 1.00 (reference) 1.00 (reference)
<11.1 3.3 99 1.08 (0.81, 1.43) 1.09 (0.80, 1.50)
‡11.1 11.1 63 1.50 (1.08, 2.09) 1.57 (1.11, 2.22)
Ptrend = 0.01
e Ptrend = 0.01
e
Ages 30–35 years
c
None 0.0 90 1.00 (reference) 1.00 (reference)
<11.1 3.3 112 1.19 (0.90, 1.59) 1.26 (0.92, 1.71)
‡11.1 11.1 29 1.21 (0.78, 1.86) 1.38 (0.87, 2.19)
Ptrend = 0.36 Ptrend = 0.16
Ages 18–22 years
d
None 0.0 167 1.00 (reference) 1.00 (reference)
<11.1 3.3 63 1.11 (0.82, 1.50) 1.17 (0.84, 1.63)
‡11.1 11.1 8 1.42 (0.69, 2.91) 1.63 (0.76, 3.50)
Ptrend = 0.28 Ptrend = 0.15
Liquor
Year before baseline
None 0.0 169 1.00 (reference) 1.00 (reference)
<15.0 4.5 68 1.09 (0.82, 1.45) 1.06 (0.78, 1.44)
‡15.0 15.0 16 0.87 (0.52, 1.47) 0.82 (0.48, 1.39)
Ptrend = 0.80 Ptrend = 0.56
Ages 30–35 years
c
None 0.0 124 1.00 (reference) 1.00 (reference)
<15.0 4.5 93 1.07 (0.81, 1.41) 1.04 (0.77, 1.40)
‡15.0 15.0 14 0.77 (0.44, 1.35) 0.75 (0.42, 1.36)
Ptrend = 0.52 Ptrend = 0.44
Ages 18–22 years
d
None 0.0 164 1.00 (reference) 1.00 (reference)
<15.0 4.5 69 0.99 (0.74, 1.32) 0.94 (0.68, 1.29)
‡15.0 15.0 5 0.62 (0.25, 1.52) 0.49 (0.19, 1.26)
Ptrend = 0.39 Ptrend = 0.17
a Adjusted for race, total energy intake, parity, oral contraceptive use, strenuous exercise, and menopausal status/hormone therapy
use; stratiﬁed by age at baseline
b Additionally adjusted for consumption of other alcohol types in the same time period
c Among women over age 35 years at baseline with non-missing data on alcohol consumption at ages 30–35 years
d Among women over age 22 years at baseline with non-missing data on alcohol consumption at ages 18–22 years
e p for non-linearity of trend > 0.05
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123Table 3 Relative risks (RRs) and 95% conﬁdence intervals (CIs) for associations between patterns of drinking speciﬁc types of alcohol
and risk of ovarian cancer
Alcohol type Time period Drinking pattern Cases (n)R R
a 95% CI
a RR
b 95% CI
b
Total alcohol
Age 30–35 years and the year before baseline
c
Never 49 1.00 (reference) —
Steady moderate 118 1.25 (0.89, 1.76) —
Decreasing 29 1.06 (0.67, 1.68) —
Increasing 27 1.10 (0.68, 1.77) —
Steady heavy 8 1.32 (0.62, 2.82) —
Age 18–22 years and the year before baseline
d
Never 55 1.00 (reference) —
Steady moderate 70 1.07 (0.74, 1.53) —
Decreasing 24 1.06 (0.65, 1.72) —
Increasing 86 1.30 (0.92, 1.84) —
Steady heavy 3 1.87 (0.58, 6.04) —
Year before baseline
0 days/week 77 1.00 (reference) —
1 to 4 days/week 98 1.25 (0.92, 1.69) —
5 to 7 days/week, £ 20 g/day 30 1.36 (0.88, 2.08) —
5 to 7 days/week, > 20 g/day 18 1.14 (0.68, 1.93) —
Beer
Age 30–35 years and the year before baseline
c
Never 163 1.00 (reference) 1.00 (reference)
Steady moderate 26 0.80 (0.53, 1.21) 0.73 (0.47, 1.13)
Decreasing 25 0.94 (0.62, 1.44) 0.88 (0.57, 1.38)
Increasing 17 1.08 (0.65, 1.79) 0.99 (0.59, 1.66)
Steady heavy 0 — —
Age 18–22 years and the year before baseline
d
Never 159 1.00 (reference) 1.00 (reference)
Steady moderate 24 1.06 (0.68, 1.64) 1.02 (0.64, 1.62)
Decreasing 34 0.95 (0.65, 1.38) 0.92 (0.61, 1.37)
Increasing 21 0.77 (0.49, 1.22) 0.71 (0.44, 1.14)
Steady heavy 0 — —
Year before baseline
e
0 days/week 199 1.00 (reference) 1.00 (reference)
1 to 4 days/week 40 0.98 (0.70, 1.39) 0.79 (0.53, 1.16)
5 to 7 days.week 1 0.33 (0.05, 2.37) 0.36 (0.05, 2.59)
Ptrend = 0.30 Ptrend = 0.14
Wine
Age 30–35 years and the year before baseline
c
Never 60 1.00 (reference) 1.00 (reference)
Steady moderate 65 1.15 (0.80, 1.64) 1.19 (0.80, 1.77)
Decreasing 34 1.25 (0.82, 1.92) 1.32 (0.82, 2.11)
Increasing 53 1.25 (0.86, 1.82) 1.29 (0.86, 1.93)
Steady heavy 19 1.54 (0.91, 2.62) 1.75 (1.00, 3.04)
Age 18–22 years and the year before baseline
d
Never 71 1.00 (reference) 1.00 (reference)
Steady moderate 29 0.98 (0.63, 1.52) 1.01 (0.62, 1.63)
Decreasing 20 1.48 (0.89, 2.45) 1.73 (1.00, 2.99)
Increasing 113 1.29 (0.95, 1.74) 1.38 (0.99, 1.92)
Steady heavy 5 2.47 (0.99, 6.19) 2.76 (1.09, 7.00)
Year before baseline
e
0 days/week 91 1.00 (reference) 1.00 (reference)
1 to 4 days/week 97 1.19 (0.89, 1.60) 1.23 (0.89, 1.71)
5 to 7 days.week 37 1.34 (0.91, 1.98) 1.45 (0.96, 2.20)
Ptrend = 0.18 Ptrend = 0.11
Liquor
Age 30–35 years and the year before baseline
c
Never 110 1.00 (reference) 1.00 (reference)
Steady moderate 47 1.13 (0.80, 1.60) 1.12 (0.76, 1.63)
Decreasing 50 1.04 (0.74, 1.46) 0.97 (0.67, 1.41)
Increasing 21 1.11 (0.69, 1.77) 1.04 (0.63, 1.70)
Steady heavy 3 0.49 (0.15, 1.54) 0.46 (0.15, 1.49)
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123race, higher total caloric intake, nulliparity, ever-use of
oral contraceptives, more physical activity, ever-use of
HT, higher SES or median family income, residence in
the Greater San Francisco Bay Area, lower body mass
index, ever-smoking of cigarettes, and higher intake of
coffee and/or tea were signiﬁcantly associated with
drinking at least one daily glass of wine, compared to
none (data not shown). However, the positive associ-
ation between wine consumption and risk of ovarian
cancer remained statistically signiﬁcant even after
adjustment for these characteristics (data not shown).
To further explore the relationship between wine
consumption and ovarian cancer risk, we stratiﬁed the
association by various potential effect modiﬁers,
including demographic characteristics and ovarian can-
cer risk factors (Table 4). There was no statistically
signiﬁcant heterogeneity in the association between in-
take of alcohol from wineat baseline and risk of ovarian
cancer by any of the factors examined. Among peri-/
post-menopausal women, we observed no association
with wine intake among those who had never used HT,
noramongthosewhousedcombinedestrogen-progestin
HT, adjusting for duration of HT use. In contrast, wo-
menwhousedunopposedestrogenHTwereattwicethe
risk of ovarian cancer ifthey drankoneglass of wine per
day at baseline, compared to wine non-drinkers. The
association was especially strong among women who
used estrogen-only HT for over 5 years (RR = 2.39
[95%CI0.97–5.89],Ptrend = 0.02),whereastherewasno
such association among women who used combination
HT for over 5 years (RR = 1.34 [95% CI 0.51–3.54],
Ptrend = 0.29). We also found that the women in the
highestquartileofSESstatewidewereatdoubletherisk
of ovarian cancer if they drank at least a glass per day of
wine, compared to none, whereas there was no such
associationamongwomeninthelowerthreequartilesof
SES.
In secondary analyses, we examined the associations
between alcohol consumption and risk of ovarian
cancer among only women who were peri- or post-
menopausal at baseline (46% of the study population,
75% of cases). In this group, we observed the same
lack of a signiﬁcant association with total alcohol, beer,
or liquor intake, along with a signiﬁcant positive
association with baseline wine intake. Likewise, when
we restricted the case population to invasive ovarian
cancer (90% of cases) or to serous ovarian cancer
(45% of cases), baseline intake of alcohol from wine,
but not from other sources, was associated with sig-
niﬁcantly increased risk of ovarian cancer.
Discussion
The lack of association between overall alcohol con-
sumption and risk of ovarian cancer in our study is
consistent with most previous studies [3–18], including
a pooled analysis of 10 prospective cohorts [19].
Alcohol consumption during ages 18–22 years, ages
30–35 years, or the year before baseline—whether
from beer, liquor, or all sources combined—was
unrelated to ovarian cancer development. Addition-
ally, changes in beer, liquor, or total alcohol con-
sumption over time, as well as frequency of drinking in
the year before baseline, did not affect ovarian cancer
risk in this cohort.
In contrast, average consumption of at least one
glass per day of wine in the year before baseline was
Table 3 continued
Alcohol type Time period Drinking pattern Cases (n)R R
a 95% CI
a RR
b 95% CI
b
Age 18–22 years and the year before baseline
d
Never 126 1.00 (reference) 1.00 (reference)
Steady moderate 32 1.12 (0.76, 1.66) 1.10 (0.71, 1.69)
Decreasing 35 0.84 (0.57, 1.23) 0.76 (0.50, 1.15)
Increasing 44 0.98 (0.69, 1.38) 0.92 (0.64, 1.33)
Steady heavy 1 0.80 (0.11, 5.77) 0.69 (0.10, 5.04)
Year before baseline
e
0 days/week 169 1.00 (reference) 1.00 (reference)
1 to 4 days/week 57 1.13 (0.83, 1.53) 1.10 (0.78, 1.55)
5 to 7 days.week 13 1.00 (0.57, 1.78) 0.73 (0.35, 1.51)
Ptrend = 0.92 Ptrend = 0.44
a Adjusted for race, total energy intake, parity, oral contraceptive use, strenuous exercise, and menopausal status/hormone therapy
use; stratiﬁed by age at baseline
b Additionally adjusted for drinking patterns of other alcohol types across the same time periods
c Among women over age 35 years at baseline with non-missing data on alcohol consumption at ages 30–35 years
d Among women over age 22 years at baseline with non-missing data on alcohol consumption at ages 18–22 years
e Excluding women with missing data on number of drinking days per week
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123Table 4 Stratiﬁed relative risks (RRs) and 95% conﬁdence intervals (CIs) for associations between wine intake in the year before
baseline and risk of ovarian cancer within participant subgroups
Characteristic (at baseline) Alcohol consumption from wine Ptrend Pheterogeneity
between subgroups
None < 11.1 g/day ‡ 11.1 g/day
Cases RR
a Cases RR
a (95% CI)
a Cases RR
a (95% CI)
a
Age
£Median (50 years) 23 1.00 27 1.07 (0.58, 1.99) 12 1.43 (0.67, 3.04) 0.34
>Median 68 1.00 72 1.10 (0.76, 1.57) 51 1.62 (1.09, 2.39) 0.01 0.95
Parity
Nulliparous 18 1.00 26 1.34 (0.69, 2.62) 13 1.56 (0.71, 3.40) 0.31
Parous 71 1.00 73 1.05 (0.73, 1.50) 48 1.57 (1.06, 2.34) 0.02 0.61
Oral contraceptive use
Never 45 1.00 39 1.00 (0.62, 1.61) 29 1.70 (1.02, 2.82) 0.03
Ever 22 1.00 14 0.76 (0.37, 1.58) 14 1.78 (0.85, 3.72) 0.09 0.54
Lifetime strenuous physical activity
£Median (1.4 hours/week) 61 1.00 58 1.07 (0.72, 1.59) 40 1.68 (1.09, 2.59) 0.01
>Median (1.4 hours/week) 30 1.00 41 1.11 (0.66, 1.86) 23 1.39 (0.77, 2.50) 0.26 0.55
Menopausal status
Pre-menopausal 21 1.00 20 0.83 (0.42, 1.65) 10 1.24 (0.55, 2.83) 0.53
Peri-/Post-menopausal 66 1.00 72 1.16 (0.80, 1.66) 51 1.72 (1.16, 2.55) 0.01 0.86
Hormone therapy (HT) use
None
b 21 1.00 22 1.27 (0.64, 2.51) 9 1.20 (0.51, 2.78) 0.73
Combination
estrogen + progestin HT
b
23 1.00 18 0.69 (0.35, 1.37) 16 1.17 (0.58, 2.34) 0.45
Estrogen-only HT
b 16 1.00 19 1.27 (0.62, 2.61) 15 2.03 (0.95, 4.35) 0.06 0.37
Region of residence
Greater Bay/Southern Coastal regions 45 1.00 62 1.20 (0.79, 1.84) 38 1.69 (1.06, 2.71) 0.02
Other California regions 46 1.00 37 0.94 (0.59, 1.52) 25 1.46 (0.87, 2.48) 0.12 0.41
Type of residence
Rural/town/small city 35 1.00 34 1.23 (0.74, 2.06) 23 1.77 (1.01, 3.11) 0.05
Metropolitan suburban/urban 54 1.00 65 1.04 (0.70, 1.55) 40 1.51 (0.97, 2.37) 0.05 0.77
Statewide percentile of socioeconomic status in census block group
c
Lower 75% 57 1.00 50 1.09 (0.72, 1.67) 24 1.35 (0.81, 2.27) 0.25
Upper 25% 32 1.00 49 1.16 (0.72, 1.88) 39 1.96 (1.19, 3.24) 0.004 0.43
Body mass index
£Median (23.5 kg/m
2) 33 1.00 46 1.31 (0.81, 2.11) 32 1.64 (0.97, 2.76) 0.07
>Median 53 1.00 52 0.97 (0.63, 1.49) 27 1.48 (0.89, 2.45) 0.10 0.69
Cigarette smoking status
Never 66 1.00 61 1.05 (0.71, 1.56) 36 1.77 (1.13, 2.78) 0.01
Ever 25 1.00 38 1.19 (0.69, 2.03) 27 1.42 (0.80, 2.50) 0.24 0.57
Dietary folate intake
£Median (307.1 lg/day)
d 23 1.00 21 0.73 (0.37, 1.43) 13 1.15 (0.54, 2.44) 0.55
>Median
d 21 1.00 23 1.16 (0.60, 2.24) 10 1.17 (0.51, 2.66) 0.75 0.74
Total folate intake
£Median (473.0 lg/day)
e 43 1.00 46 1.07 (0.68, 1.70) 25 1.34 (0.78, 2.30) 0.27
>Median
e 41 1.00 48 1.20 (0.77, 1.89) 37 2.07 (1.29, 3.35) 0.002 0.43
a Adjusted for race, total energy intake, parity, oral contraceptive use, strenuous exercise, menopausal status/hormone therapy use,
and consumption of beer and liquor in the past year; stratiﬁed by age at baseline
b Including peri-/post-menopausal women only
c See Methods for deﬁnition
d Excluding all multivitamin users (i.e., women consuming supplemental folate)
e Excluding short-term multivitamin users (i.e., women consuming supplemental folate for < 2 years)
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123associated with elevated risk of ovarian cancer, while
wine intake at ages 30–35 years or 18–22 years was
associated with nonsigniﬁcantly increased risk. The
positive association with baseline wine intake persisted
after adjustment for total alcohol intake, suggesting
that the apparent effect of wine on ovarian cancer risk
was independent of alcohol content. The association
was also unchanged by further adjustment for charac-
teristics and behaviors associated with wine drinking in
this cohort, and was not signiﬁcantly modiﬁed by
reproductive characteristics, demographic factors, or
folate intake. However, there was a signiﬁcant positive
association between wine consumption and ovarian
cancer risk among peri-/post-menopausal women who
used unopposed estrogen HT, whereas there was no
such association among peri-/post-menopausal women
who did not use HT or used combined estrogen-pro-
gestin HT. Wine consumption was also associated with
increased ovarian cancer risk among women of high
SES, but not among women of relatively low SES.
To our knowledge, no other study of ovarian cancer
has examined alcohol consumption at various ages or
drinking patterns over time. A positive association
between wine consumption and risk of ovarian cancer
has previously been detected in two case–control
studies [15, 49], although both of those studies reported
a positive association with total alcohol intake as well.
In contrast, two case–control studies [14, 24] and one
cohort study (among women with high dietary folate
intake) [17] found an inverse association between wine
consumption and ovarian cancer risk. However, there
was no association with wine (or total alcohol) con-
sumption in other studies [13, 18, 19].
Few previous studies have examined modiﬁcation of
the association between alcohol consumption and risk
of ovarian cancer. A pooled analysis of 529,638 women,
including 2,001 incident ovarian cancer cases, found no
interaction between alcohol intake and oral contra-
ceptive or HT use, parity, menopausal status, folate
intake, BMI, or smoking [19]. In contrast, a case–con-
trol study found that an inverse association between
wine consumption and ovarian cancer risk was signiﬁ-
cantly stronger in women who were more highly edu-
cated, had never smoked, or had used oral
contraceptives—characteristics that describe the
majority of CTS cohort members—but found no het-
erogeneity by menopausal status, BMI, or HT use [24].
Unlike us, others reported an interaction with folate
intake [16, 17, 25] or heterogeneity by histologic sub-
type of ovarian cancer [14, 15], although others did not
[3, 12, 19, 24]. We lacked sufﬁcient cases to perform
detailed analyses of ovarian cancer histologic subtypes
other than the most common serous type.
The restriction of the positive association between
wine intake and ovarian cancer risk to peri-/post-men-
opausal women taking estrogen-only HT suggests a
biological mechanism involving estrogen. Likewise, the
restriction of the association to women of high SES may
reﬂect reproductive characteristics and/or HT use
favoring increased estrogen levels in higher-SES
women.Ahighbackgroundlevelofcirculatingestrogen,
compounded by an upsurge of estrogen resulting from
alcohol consumption [1], may promote ovarian carci-
nogenesis. Furthermore, the lack of an interaction be-
tween wine intake and use of estrogen-progestin HT
could be explained by a protective effect of progestin
against ovarian cancer. Phytochemicals, such as resve-
ratrol, in red wine have been considered as promising
cancer preventive agents due to their anti-estrogenic,
antioxidant, anti-proliferative, and other anti-carcino-
genic effects [50, 51]. However, such phytochemicals
have multifarious effects, including pro-estrogenic
activityand possible genotoxicity [52–54];thus, both the
potentially beneﬁcial and potentially harmful effects
of phytochemicals on cancer development must be
consideredtogether.Inthepresentanalysis,wewerenot
able to distinguish red from white wine intake.
Our ﬁndings should be interpreted in light of some
limitations. It is possible that the observed positive
association between wine consumption and ovarian
cancer risk was due to confounding by unmeasured
characteristics beyond those for which we attempted to
adjust, or by residual confounding or chance. Our ef-
forts to fully evaluate effect modiﬁers or confounders
of the association between wine consumption and
ovarian cancer risk were partly hampered by the lack
of heterogeneity in some characteristics among CTS
participants. The proportion of women who drank beer
or liquor was low, although the range of total alcohol
intake was adequate to reveal a signiﬁcant positive
association with risk of breast cancer in an earlier
analysis [37]. Even though reporting of alcohol intake
in the past year using our questionnaire has been val-
idated, we were not able to assess the reliability or
validity of self-reported alcohol consumption at earlier
ages, which may be difﬁcult to recall, especially among
older women. Misclassiﬁcation of distant past alcohol
intake may explain the absence of a signiﬁcant asso-
ciation between wine drinking at earlier ages and
ovarian cancer risk. Nevertheless, it is unlikely that any
exposure misclassiﬁcation differed systematically
between ovarian cancer cases and non-cases, since all
information was assessed prospectively.
In summary, given the lack of association between
overall alcohol consumption and ovarian cancer risk
in our study, further investigations are necessary to
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123determine whether ingredients of wine, but not beer
or liquor, foster ovarian cancer development; whe-
ther correlates of wine drinking not measured or
imperfectly measured in our study population are
associated with ovarian cancer risk; or if an associ-
ation is largely due to the apparent interaction be-
tween wine consumption and unopposed estrogen
HT use and/or other characteristics of women of
high SES. If the observed association between wine
drinking and ovarian cancer risk is due to con-
founding, then there may exist an as-yet unidentiﬁed
ovarian cancer risk factor that is also associated with
wine drinking. On the other hand, if the interactions
with estrogen HT use and SES are conﬁrmed, there
may be a biological basis for the increased risk of
ovarian cancer among wine drinkers with high
endogenous and exogenous estrogen levels. However,
if alcohol consumption is indeed unrelated to ovarian
cancer development but positively associated with
the risk of breast cancer, then differences in the
hormonal and non-hormonal triggers between these
two malignancies may help us understand the car-
cinogenic effects of alcohol on hormonally responsive
tissue. Further understanding of the complex rela-
tionships among steroid hormone levels, metabolism
of alcohol and wine, and carcinogenesis will help
clarify what role, if any, alcohol and wine play in the
development of ovarian cancer.
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